Epidermal barrier defects link atopic dermatitis with altered skin cancer susceptibility.
Atopic dermatitis can result from loss of structural proteins in the outermost epidermal layers, leading to a defective epidermal barrier. To test whether this influences tumour formation, we chemically induced tumours in EPI-/- mice, which lack three barrier proteins-Envoplakin, Periplakin, and Involucrin. EPI-/- mice were highly resistant to developing benign tumours when treated with 7,12-dimethylbenz(a)anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA). The DMBA response was normal, but EPI-/- skin exhibited an exaggerated atopic response to TPA, characterised by abnormal epidermal differentiation, a complex immune infiltrate and elevated serum thymic stromal lymphopoietin (TSLP). The exacerbated TPA response could be normalised by blocking TSLP or the immunoreceptor NKG2D but not CD4+ T cells. We conclude that atopy is protective against skin cancer in our experimental model and that the mechanism involves keratinocytes communicating with cells of the immune system via signalling elements that normally protect against environmental assaults.DOI: http://dx.doi.org/10.7554/eLife.01888.001.
Centre for Stem Cells and Regenerative Medicine, King's College London, London, United Kingdom Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom.
Sara
S
Cipolat
Centre for Stem Cells and Regenerative Medicine, King's College London, London, United Kingdom Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom.
Esther
E
Hoste
Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom Department of Dermatology, Hokkaido University, Sapporo, Japan.
Ken
K
Natsuga
Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom Department of Dermatology and Venereology, Otto von Guericke University Magdeburg, Magdeburg, Germany.
Sven R
SR
Quist
Centre for Stem Cells and Regenerative Medicine, King's College London, London, United Kingdom fiona.watt@kcl.ac.uk.
Fiona M
FM
Watt
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D002450:Cell Communication; D002454:Cell Differentiation; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D016207:Cytokines / Q000097:blood; D003876:Dermatitis, Atopic / Q000235:genetics / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D004195:Disease Models, Animal; D004817:Epidermis / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D015603:Keratinocytes / Q000276:immunology / Q000378:metabolism; D008565:Membrane Proteins / Q000172:deficiency* / Q000235:genetics; D057507:Mice, 129 Strain; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008819:Mice, Nude; D055655:NK Cell Lectin-Like Receptor Subfamily K / Q000378:metabolism; D010212:Papilloma / Q000139:chemically induced / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D010539:Permeability; D051179:Plakins / Q000172:deficiency* / Q000235:genetics; D011498:Protein Precursors / Q000172:deficiency* / Q000235:genetics; D015398:Signal Transduction; D012878:Skin Neoplasms / Q000139:chemically induced / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D013755:Tetradecanoylphorbol Acetate; D013997:Time Factors; D000094632:Thymic Stromal Lymphopoietin
D016207:Cytokines; C527086:Klrk1 protein, mouse; D008565:Membrane Proteins; D055655:NK Cell Lectin-Like Receptor Subfamily K; D051179:Plakins; C110037:Ppl protein, mouse; D011498:Protein Precursors; C100754:envoplakin; D015127:9,10-Dimethyl-1,2-benzanthracene; C032253:involucrin; D013755:Tetradecanoylphorbol Acetate; D000094632:Thymic Stromal Lymphopoietin; C000721967:TSLP protein, mouse
cancer; eczema; skin